Caseware UK (AP4) 2023.0.135 2023.0.135 false2023-01-01falseNo description of principal activity912falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 01952605 2023-01-01 2023-12-31 01952605 2022-01-01 2022-12-31 01952605 2023-12-31 01952605 2022-12-31 01952605 c:CompanySecretary1 2023-01-01 2023-12-31 01952605 c:Director2 2023-01-01 2023-12-31 01952605 c:Director5 2023-01-01 2023-12-31 01952605 c:Director6 2023-01-01 2023-12-31 01952605 c:Director6 2023-12-31 01952605 c:RegisteredOffice 2023-01-01 2023-12-31 01952605 c:Agent1 2023-01-01 2023-12-31 01952605 c:Agent2 2023-01-01 2023-12-31 01952605 d:PlantMachinery 2023-01-01 2023-12-31 01952605 d:PlantMachinery 2023-12-31 01952605 d:PlantMachinery 2022-12-31 01952605 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 01952605 d:CurrentFinancialInstruments 2023-12-31 01952605 d:CurrentFinancialInstruments 2022-12-31 01952605 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 01952605 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 01952605 d:ShareCapital 2023-12-31 01952605 d:ShareCapital 2022-12-31 01952605 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 01952605 d:RetainedEarningsAccumulatedLosses 2023-12-31 01952605 d:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 01952605 d:RetainedEarningsAccumulatedLosses 2022-12-31 01952605 d:RetainedEarningsAccumulatedLosses 2022-01-01 01952605 c:FRS102 2023-01-01 2023-12-31 01952605 c:Audited 2023-01-01 2023-12-31 01952605 c:FullAccounts 2023-01-01 2023-12-31 01952605 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure

Registered number: 01952605









Buckman Laboratories Limited









Annual Report and Financial Statements

for the year ended 31 December 2023

 
Buckman Laboratories Limited
 
 
Company Information


Directors
JM Gustin 
JE Scharff 
CL Knutton 




Company secretary
JM Gustin



Registered number
01952605



Registered office
3 Stockport Exchange

Stockport

Cheshire

United Kingdom

SK1 3GG




Independent auditor
Ascendis Audit Limited

Unit 3, Building 2

The Colony

Wilmslow

Cheshire

SK9 4LY




Bankers
Bank Mendes Gans N.V.
Herengracht 619

1017 CE Amsterdam

Netherlands





ING Bank N.V

60 London Wall

London

EC2M STQ




Solicitors
Baker & McKenzie Solicitors
100 New Bridge Street

London

EC4V 6JA





 
Buckman Laboratories Limited
 

Contents



Pages
Directors' Report
 
1
Directors' Responsibilities Statement
 
2
Independent Auditor's Report
 
3 - 7
Income Statement
 
8
Statement of Financial Position
 
9
Notes to the Financial Statements
 
10 - 15


 
Buckman Laboratories Limited
 
 
Directors' Report
For the year ended 31 December 2023

The directors present their Annual Report and the audited financial statements for the year ended 31 December 2023.

Directors

The directors who served during the year and up to the date of signing were:

JM Gustin 
JE Scharff 
CL Knutton (appointed 6 September 2023)
M Connor (resigned 6 September 2023) 
                                                                                                                                              

Statement to the Auditor

 Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:
• so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and 
• the director has taken all steps that ought to have been taken as a director in order to be aware of any relevant audit            information and to establish that the Company's auditor is aware of that information.

Auditor

Ascendis Audit Limited will be proposed for re-appointment under Section 455 of the Companies Act 2006.

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 



JM Gustin
Director

Date: 11 September 2024

Page 1

 
Buckman Laboratories Limited
 
 
Directors' Responsibilities Statement
For the year ended 31 December 2023

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including FRS 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:

select suitable accounting policies and then apply them consistently;

make judgements and accounting estimates that are reasonable and prudent; and


prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Page 2

 
Buckman Laboratories Limited
 
 
Independent Auditor's Report to the Members of Buckman Laboratories Limited
 

Report on the audit of the financial statements


Opinion
We have audited the financial statements which comprise:
• the Income Statement; 
• the Statement of Financial Position; 
• the related notes 1 to 8.
In our opinion the financial statements of Buckman Laboratories Limited (the ‘company’):
• give a true and fair view of the state of the company’s affairs as at 31 December 2023 and of its profit for the year    then ended; 
• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice,     including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic   of Ireland” and
• have been prepared in accordance with the requirements of the Companies Act 2006.
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. 
We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council’s (the ‘FRC’s’) Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.






Page 3

 
Buckman Laboratories Limited
 
 
Independent Auditor's Report to the Members of Buckman Laboratories Limited (continued)

Other information


The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 
We have nothing to report in respect of these matters.


Responsibilities of directors
 

As explained more fully in the directors’ responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 
In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.


Page 4

 
Buckman Laboratories Limited
 
 
Independent Auditor's Report to the Members of Buckman Laboratories Limited (continued)

Auditor’s responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 
The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following;
- the nature of the industry, control environment and business performance;
- our enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the company's documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.
As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following area: revenue recognition. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.
We also obtained an understanding of the legal and regulatory framework that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included REACH, the Companies Act 2006, and UK tax legislation and regulations issued by HMRC.
In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty. 
Audit response to risks identified:-
Our procedures to respond to risks identified included the following:
- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments;
- assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and 
- evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit. ln addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty. 
 
Page 5

 
Buckman Laboratories Limited
 
 
Independent Auditor's Report to the Members of Buckman Laboratories Limited (continued)


There are inherent limitations in our audit procedures described above. The more removed the laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to inquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.
A further description of our responsibilities for the audit of the financial statements is located on the FRC’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.


Report on other legal and regulatory requirements
 

Opinions on other matters prescribed by the Companies Act 2006


In our opinion, based on the work undertaken in the course of the audit:
• the information given in the Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
• the Director's Report has been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Director's Report.


Matters on which we are required to report by exception
 

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:
• adequate accounting records have not been kept, or returns adequate for our audit have not been received from    branches not visited by us; or
• the financial statements are not in agreement with the accounting records and returns; or
• certain disclosures of directors’ remuneration specified by law are not made; or
• we have not received all the information and explanations we require for our audit; or
• the directors were not entitled to prepare the financial statements in accordance with the small companies regime and  take advantage of the small companies’ exemptions in preparing the Directors’ Report and from the requirement to    prepare a strategic report.
We have nothing to report in respect of these matters.


Page 6

 
Buckman Laboratories Limited
 
 
Independent Auditor's Report to the Members of Buckman Laboratories Limited (continued)

Use of our report
 

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.





Paul Allan Byrne BA (Double Hons) FCA (Senior Statutory Auditor)
for and on behalf of
Ascendis Audit Limited
Statutory Auditor
Unit 3, Building 2
The Colony
Wilmslow
Cheshire
SK9 4LY

17 September 2024
Page 7

 
Buckman Laboratories Limited
 
 
Income Statement
For the year ended 31 December 2023

2023
2022
Note
£
£

  

Turnover
  
6,716,058
5,292,259

Cost of sales
  
(4,978,940)
(3,736,749)

Gross profit
  
1,737,118
1,555,510

Administrative expenses
  
(1,643,008)
(1,532,612)

Operating profit
  
94,110
22,898

Interest receivable and similar income
  
2,996
39

Interest payable and similar expenses
  
(514)
-

Profit before tax
  
96,592
22,937

Tax on profit
  
(21,124)
(4,070)

Profit after tax
  
75,468
18,867

  

  

Retained earnings at the beginning of the year
  
1,268,462
1,249,595

  
1,268,462
1,249,595

Profit for the year
  
75,468
18,867

Retained earnings at the end of the year
  
1,343,930
1,268,462
All above activities arise from continuing operations.


There was no other comprehensive income for 2023 (2022: £NIL). Accordingly, a statement of Other Comprehensive Income has not been presented.
The notes on pages 10 to 15 form part of these financial statements.

Page 8

 
Buckman Laboratories Limited
Registered number:01952605

Statement of Financial Position
As at 31 December 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
330,087
185,574

  
330,087
185,574

Current assets
  

Stocks
  
152,971
45,645

Debtors: amounts falling due within one year
 5 
1,635,296
1,328,150

Cash at bank and in hand
  
311,475
541,221

  
2,099,742
1,915,016

Creditors: amounts falling due within one year
 6 
(918,784)
(673,623)

Net current assets
  
 
 
1,180,958
 
 
1,241,393

Total assets less current liabilities
  
1,511,045
1,426,967

Provisions for liabilities
  

Deferred tax
  
(17,115)
(8,505)

  
 
 
(17,115)
 
 
(8,505)

Net assets
  
1,493,930
1,418,462


Capital and reserves
  

Called up and paid share capital
  
150,000
150,000

Profit and loss account
  
1,343,930
1,268,462

  
1,493,930
1,418,462


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small
companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


JM Gustin
Director

Date: 11 September 2024

The notes on pages 10 to 15 form part of these financial statements.

Page 9

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

1.


General information

Buckman Laboratories Limited ("the Company") is a private company limited by shares and incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the registered office is 3 Stockport Exchange, Stockport, Cheshire, SK1 3GG. The company's registered number is 01952605. The Company does not have a principal place of business.
 
Amounts in these financial statements are rounded to the nearest pound sterling. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Going concern

The Company generates revenue through the sale of chemicals to customers based in the United Kingdom. The chemicals that it sells are produced by its immediate parent company, Buckman Laboratories S.A. and are shipped directly from Belgium to the customer in respect of each sale.  The Company incurred a profit after tax in 2023, and reported a net current assets and net assets position as at 31 December 2023.  
Whilst the Directors do not have any concerns over the Company’s ability to continue as a going concern, they acknowledge that the future trading of the Company is dependent upon its continued partnership with the Group in fulfilling the orders that its customers place. As such, in making the going concern assessment, the Directors have sought confirmation from the ultimate parent, Bulab Holdings Inc. that it will provide financial support to the Company, in the event that it is required over the 12 months from the date of signing of the financial statements, as evidence of the Group’s strategic commitment to the UK business. 
In seeking this support the Directors have not only considered the intention of the ultimate parent company to provide financial support, should the need arise, but also its ability to do so. They have reviewed the Group’s liquidity and its forecasts for the period in question, as well as the assumptions that underpin them and are satisfied that this ability is well assured. 
Accordingly, despite the current uncertain economic climate, the Directors have prepared these financial statements on a going concern basis.
 

Page 10

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

2.Accounting policies (continued)

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is pound sterling as this is the currency of the primary economic environment in which the Company operates.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Income Statement except when deferred in Other Comprehensive Income as qualifying cash flow hedges.
Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Income Statement within administrative expenses. All other foreign exchange gains and losses are presented in the Income Statement within administrative expenses.

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:
• the Company has transferred the significant risks and rewards of ownership to the buyer;
• the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the Company will receive the consideration due under the transaction; and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Income Statement on a straight line basis over the lease term.

  
2.6

Borrowing costs

All borrowing costs are recognised in the Income Statement in the year in which they are incurred.

Page 11

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

2.Accounting policies (continued)

  
2.7

Pensions

Defined contribution pension plan
The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.
The contributions are recognised as an expense in the Income Statement when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

  
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Income Statement  except that a charge attributable to an item of income and expense recognised as Other Comprehensive Income or to an item recognised directly in Equity is also recognised in Other Comprehensive Income or directly in Equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date in the countries where the Company operates and generates income.
Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of Financial Position date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.
 
Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

 
2.9

Tangible fixed assets

Tangible fixed assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.
Depreciation is not charged on assets under construction.

Page 12

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

2.Accounting policies (continued)


2.9
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the sum of the years digits.

Depreciation is provided on the following basis:

Plant and machinery
-
sum of the years digits

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.



 
2.10

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. 
At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the Income Statement.

 
2.11

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Balance sheet.

 
2.12

Financial instruments

The Company only has basic financial instruments which are stated at amortised cost.


3.


Employees

The average monthly number of employees, including directors, during the year was 9 (2022 -12).

Page 13

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

4.


Tangible fixed assets





Plant and machinery

£



Cost


At 1 January 2023
827,497


Additions
193,426


Disposals
(86,867)



At 31 December 2023

934,056



Depreciation


At 1 January 2023
641,923


Charge for the year on owned assets
48,913


Disposals
(86,867)



At 31 December 2023

603,969



Net book value



At 31 December 2023
330,087



At 31 December 2022
185,574

Additions include £210,178 (2022: £25,044) of assets under construction which have not been depreciated.

Page 14

 
Buckman Laboratories Limited
 
 
Notes to the financial statements
For the year ended 31 December 2023

5.


Debtors: amounts falling due within one year

2023
2022
£
£


Trade debtors
1,042,475
1,207,332

Amounts owed by parent undertakings
588,438
110,618

Other debtors
3,082
-

Prepayments
1,301
10,200

1,635,296
1,328,150


The amounts owed by parent undertakings are repayable on demand and are non-interest bearing.


6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
245,027
279,088

Corporation tax
11,859
15,385

Other taxation and social security
258,182
294,709

Accruals and deferred income
403,716
84,441

918,784
673,623



7.


Pension commitments

The pension charge for the year of £40,446 (2022: £51,948) was incurred entirely in respect of a defined contribution scheme. At the year end £17,494 (2022: £nil) was due to the scheme.


8.


Controlling party

The company is a subsidiary undertaking of Buckman Laboratories S.A., incorporated in Belgium, as 99.9% of the shares are owned by Buckman Laboratories S.A. The address of the registered office is Wondelgemkaai 157, 9000 Gent, Belgium.
The company's ultimate parent company is Bulab Holdings Inc., incorporated in the United States of America. The address of the registered office is 1256 North McLean Blvd, Memphis, TN 38108, United States of America.
The parent undertaking of the largest group, which includes the company and for which group financial statements are prepared is Bulab Holdings Inc.
Copies of the financial statements of both companies can be obtained from the Company on request.

 
Page 15